Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist
A Phase I Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Metastatic Castration Resistant Prostate Cancer
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Study Type: Treatment
Phase: III
NCTID: NCT05838716
Principal Investigator:
Elizabeth Wulff-Burchfield
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sleep Hygiene Education, ReadiWatchTM Actigraphy, And Telehealth Cognitive Behavioral Training For Insomnia Effect, On Symptom Relief For Men With Prostate Cancer Receiving Androgen Deprivation Therapy ADT SHERE-Relief 2.
Study Type: Supportive Care
Phase: Feasibility/Pilot
NCTID: NCT05582759
Principal Investigator:
Jamie Myers
Quantifying Optimal Relugolix Duration with Radiation in High Risk Prostate Cancer QURE-PC
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study ICON study number: 0798/0661
A Phase III, Multi-center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA IT PET/CT in Men with Biochemical Recurrence of Prostate Cancer
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy ADT in High Risk Prostate Cancer with Initial Phase I NADIR Randomized Phase II Trial of Niraparib with Standard Combination Androgen Deprivation Therapy ADT and Radiotherapy in High Risk Prostate Cancer with Initial Phase I
Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
Study Type: Health Services
Phase: III
NCTID: NCT03860961
Principal Investigator:
Ronald Chen